These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1278 related articles for article (PubMed ID: 19156838)

  • 21. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y; Takeda S
    Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
    Takeshima Y; Yagi M; Matsuo M
    Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
    Mitrpant C; Fletcher S; Iversen PL; Wilton SD
    J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exon skipping quantification by real-time PCR.
    Ferlini A; Rimessi P
    Methods Mol Biol; 2012; 867():189-99. PubMed ID: 22454062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene.
    Echigoya Y; Lim KRQ; Melo D; Bao B; Trieu N; Mizobe Y; Maruyama R; Mamchaoui K; Tanihata J; Aoki Y; Takeda S; Mouly V; Duddy W; Yokota T
    Mol Ther; 2019 Nov; 27(11):2005-2017. PubMed ID: 31416775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
    Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
    J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M; Yokota T
    Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M; Takeshima Y; Nishio H
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
    Wood MJ
    Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y; Yagi M; Wada H; Matsuo M
    Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.